Special Issue

Emerging Anti-cancer Therapeutics and Cancer Drug Resistance

Message from the Guest Editors

During the past two decades, anti-cancer therapy has evolved from traditional cytotoxic chemotherapy to selective targeted therapy and antibody-based cancer immunotherapy that target not only the cancer cells, but also the cancer microenvironment. Novel anti-cancer therapeutics, such as covalent inhibitors, proteolysis targeting chimeras (PROTACs), antibody-drug conjugates (ADCs) and chimeric antigen receptor (CAR) T-cell therapy, have ushered in a new era of cancer medicine. This Special Issue aims to cover research topics on emerging anti-cancer therapeutics such as innovative targeted therapies, novel immunotherapies and rational combinatorial therapies. The goal is to improve our understanding of the critical role of the tumor heterogeneity, genetic/epigenetic adaptive response, and tumor microenvironment in defining the efficacy of anti-cancer therapeutics as well as mediating drug resistance. It also aims to reveal novel therapeutic targets for cancer treatment and overcoming drug resistance. Basic cancer biologists and physician scientists are welcome to contribute to this Special Issue.

Guest Editors

Dr. Lingtao Jin

Department of Anatomy and Cell Biology, College of Medicine, University of Florida, Gainesville, FL 32611, USA

Dr. Guangrong Zheng

Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL 32611, USA

Deadline for manuscript submissions

closed (31 March 2022)



Life

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 6.0
Indexed in PubMed



mdpi.com/si/94783

Life
Editorial Office
MDPI, Grosspeteranlage 9
4052 Basel, Switzerland
Tel: +41 61 683 77 34
life@mdpi.com

mdpi.com/journal/ life





Life

an Open Access Journal by MDPI

Impact Factor 3.4 CiteScore 6.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Life (ISSN 2075-1729) is an international, peer-reviewed open access journal that publishes scientific studies related to fundamental themes in life sciences. Some papers are published individually, while others are submitted for inclusion in special issues with guest editors. You are invited to contribute a research article, essay, or a review to be considered for publication.

Editor-in-Chief

Prof. Dr. Lluís Ribas de Pouplana

Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, 08028 Barcelona, Spain

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Biology) / CiteScore - Q1 (Paleontology)

